Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

Benekli M., YALÇIN Ş., ÖZKAN M., ELKIRAN E. T., Sevinc A., ÇABUK D., ...Daha Fazla

ONCOTARGETS AND THERAPY, cilt.8, ss.1-5, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2015
  • Doi Numarası: 10.2147/ott.s70670
  • Dergi Adı: ONCOTARGETS AND THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1-5
  • Anahtar Kelimeler: advanced thyroid cancer, sorafenib, overall survival, PHASE-II TRIAL, ENDOTHELIAL GROWTH-FACTOR, DOUBLE-BLIND, INHIBITORS, CARCINOMA
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication.